I got caught by surprise with Conjuchem's move as well and I don't like the long extended silence of the new CEO. However, as you say, the technology looks interesting. It has been suggested that they might clash with AMLN over the patent for Exendin which I assume is true but haven't been able to confirm. Any idea?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.